Semaglutide improves MASLD and MASH in people with HIV: The SLIM LIVER study.

HIV MedJul 28, 2026 (epub)
Clinical ResearchGastroenterologyInfectious Diseases

Jordan E Lake, Douglas W Kitch, Amy Kantor et al.

✦ AI-curated · Sources linked

In 30 seconds

The SLIM LIVER study, a phase 2b open-label trial, evaluated the effects of semaglutide on metabolic dysfunction-associated steatotic liver disease (MASLD) in people with HIV. Among 36 participants, 24 weeks of treatment resulted in significant improvement in MASLD severity as assessed by serum metabolomic profiling, indicating potential histologic improvements.

Key findings

  • 24 weeks of semaglutide treatment led to significant improvement in MASLD severity across all categories.
  • Participants showed a clinical response with greater than 2.27 kg weight loss.
  • Metabolomic profiling was performed using the OWLiver® panel.

Why it matters

This study highlights the potential of semaglutide as an effective treatment for MASLD in individuals with HIV, providing a non-invasive method for monitoring disease severity through metabolomic profiling.

Source

PubMed · PMID 42517548

Published in HIV Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.